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Neurofibromatosis type 1 (NF1) is a disease 
characterized by increased tumorigenesis 
susceptibility, caused by mutations of the 
oncosuppressor gene NF1. The glomus tumor 
(GT) is a rare, very painful mesenchymal 
neoplasm, arising from the glomus body. In 
recent years, it has been highlighted the 
association between NF1 and GT. We report a 
case of a man aged 65 years, suffering from 
NF1, with intense pain at the thenar eminence 
of the right hand, successfully treated with the 
excision of the mass.  
Keywords: Glomic Tumor, 
Neurofibromatosis, Biallelic Inactivation, 
Finger, Pain. 
Introduction 
Neurofibromatosis type 1 (NF1) is an 
autosomal dominant disorder, with an 
incidence of 1/2,500–3,000 births and a 
prevalence of approximately 1/4,000-5,000 
individuals 1. It is caused by mutations in 
the NF1 tumor suppressor gene, located on 
chromosome 17 (17q11.2), which encodes 
neurofibromin (nf), a protein able to 
downregulate the Ras-Raf/MAPK signaling 
pathway that activates cell proliferation 2. 
Mutations of the NF1 gene result in alteration 
or loss of function of negative regulator of 
growth and cellular differentiation of nf, 
leading to uncontrolled cell proliferation and 
increased risk of developing cancer 3,4 . 
The glomic or glomus tumors (GT) are 
composed of benign mesenchymal 
neoplasms, arising from glomus cells that are 
modified smooth muscle cells of the glomus 
body (Masson glomus), a thermoregulatory 
structure of the dermis 5.  
Glomus bodies are mostly found in the palm 
of the hand and sole of the foot, reaching the 
highest concentration in the fingers, 
especially in the nail bed and the distal 
phalanx, which are elective sites of glomus 
tumor 6 . 
It represents almost 2% of all soft tissues 
tumors and from 1 to 5% of all hand 
neoplasms, with high incidence in women 
aged between 20 and 40 years 7. The GT 
generally looks like a solid, encapsulated, 
spherical mass, located in the deep dermis or 
subcutaneous tissue, typically measuring 2-3 
mm in diameter, but it can reach more than 15 
mm. Klaber et al. in 1938 reported the first 
case of GT in patients with NF1 8. 
The common ultrasonographic (US) features 
of glomus tumors include a small (≤1.0 cm), 
solid, homogeneously hypoechoic or 
isoechoic, well-demarcated nodule; 
hypervascularity on color or power Doppler 
imaging; and bony erosion of the underlying 
phalangeal bone 9. 
MR imaging showed localization of a hypo-
intense (dark) lesion that was well marginated 
and oval-shaped on T1-weighted images. On 
T2-weighted images, these lesions appeared 
brighter and hyper-intense with a hypo-
intense rim 10 . 
Translational Medicine @ UniSa - ISSN 2239-9747 2015, 11(12): 63-68 
 
64 
Università degli Studi di Salerno  
 
In the current study, we report an atypical 
location of GT of the hand in NF1 and we 
review the literature. 
 
Case report 
A man aged 65 with NF1 underwent to our 
institution complaining for severe pain of the 
thenar eminence in the right hand (Figures 1-
2). He had previously consulted other 
specialists (rheumatologist, physiatrist, 
neurologist, psychiatrist), without a specific 
diagnosis. 
Pain was triggered by a simple touch and low 
heat. Inspection highlighted a slight nodular 
swelling of the thenar eminence without any 
changes of the color and trophism of the skin 
(Figure 1). 
The signs of triad of Carroll 11 
(hypersensitivity to cold Cold Sensitivity 
Test, paroxysmal pain, compression pain 
Love Test 12. Pain was attenuated after 
application of a tourniquet (Hildreth’s test) 
13]. X-ray did not show bony alteration. 
The vascular origin of the neoformation was 
confirmed by thermographic examination that 
recorded an increase of the local heat in an 
unusual site for GT 14 (Figure 3).  
Surgical excision was performed in local 
anesthesia with an incision of 1 cm at the 
level of the palpable mass, which was found 
to be very shallow (Figure 4).  
The excised neoformation appeared 
macroscopically as a solid highly 
vascularized, encapsulated mass of 3 cm with 
a reddish-brown coloration (Figure 4). A 
careful inspection of the surrounding 
subcutaneous tissues with microsurgical 
glasses did not show additional anatomical 
abnormalities.  
The patient had a significant pain reduction 
within 24 hours and a complete resolution of 
all symptoms in one week. Histological 
examination showed blood vessels 
surrounded by a proliferation of small round 
cells with dark nuclei in a myxoid stroma, 
confirming the diagnosis of glomus tumor 
(Figure 5). 
Discussion 
The GT is a rare neoplasm whose incidence is 
underestimated due to misdiagnosis of the 
mass as a neuroma, melanoma, gouty tophi, 
angioleiomyoma, neurofibromas, foreign 
bodies, ganglions, etc. From clinical history 
arise a mean duration of symptoms of 10 
years and the patient often consult several 
specialists (orthopedic, rheumatologist, 
physiatrist, neurologist), including often a 
psychiatrist, before to achieve the proper 
diagnosis 15 . 
Pain and hand dysfunction mainly affect daily 
manual activities, resulting in a severe 
deterioration of patient’s quality of life of 
patients. The intense pain, often referred as 
"hammer blow", usually lasts less than a 
minute, but the quick reappear of the local 
symptoms generates a state of anxiety 
pending a new triggering event that may 
recur. 
For these reasons, the patients pose the hand 
in defense from external stimuli in different 
ways such as keeping the hand closed in a 
sleeve, wrapping it in a cloth, or leaving it 
permanently in a glove. Moreover, the clinical 
diagnosis is facilitated by the recognition of at 
least 2 out of 3 symptoms of the 
aforedescribed triad of Carroll and the 
positivity of the Hildreth’s Test 16,17. 
The Hildreth’s test, easy to perform, has a 
high sensitivity (71.4%), a specificity of 
100% and an accuracy of 78%; the Love’s pin 
test, although with a sensitivity of 100% and 
an accuracy of 78%, has a specificity of 0%; 
the Cold sensitivity Test has sensitivity, 
specificity and accuracy of 100%. For this 
reason, it is always advisable to perform all 
aforementioned tests 18. 
Diagnostic imaging, as MRI and US, is of 
great assistance to a mainly clinical diagnosis, 
except for those atypical localizations 
(cutaneous and visceral) 19. The literature 
shows a strong correlation between GT and 
NF1 20-24.  
In patients with NF1, the onset of a GT is 
related to biallelic inactivation of the NF1 
gene, presumably due to errors during DNA 
replication in mitosis, that leads to the 
activation of a cascade of growth factors 
depending on Ras-Raf/MAPK pathway 20. 
This signaling pathway stimulates the growth 
of glomic cells, playing a key role in the 
development of GT in patients with NF1 21. 
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The differential diagnosis is made with 
neurofibromas, characteristic skin lesion of 
the NF1, from which it differs in its usual 
location at the distal phalanges, and the 
painful symptoms that are triggered by low 
intensity stimuli. 
However, Maertens et al 22 in 2007 showed 
the presence of a somatic mosaicism in NF1, 
mainly confined to neural crest cells, or 
belonging to the neural crest origin, 
confirmed by molecular analysis. 
Neurofibromas of Schwann cells and 
melanocytes taken from the cafe-au-lait spots 
showed biallelic inactivation of the NF1 gene 
23. 
Due to the extreme similarity of the 
pathogenetic mechanisms with neurofibromas 
and stains, Brems et al 24 hypothesized that 
the GT might arise from myofibroblasts 
derived from the neural crest stem cells. 
Furthermore, it was demonstrated that the 
silencing of the NF1 gene induces increased 
expression of vascular endothelial growth 
factor (VEGF) 25,26, further clarifying the 
reasons of occurrence of a hypervascularized 
neoplasm, such as the GT. 
In general, NF1-associated glomus tumors 
share many histologic similarities to sporadic 
ones: namely the cuboidal cells surrounding 
blood vessels, smooth muscle actin (SMA) 
positivity, and benign appearing rounded 
nuclei with moderate to abundant cytoplasm 
27. Since the presence of GT is 
underestimated, is not uncommon in the 
clinical practice to leave these patients with a 
severe pain for long time. 
Individuals with NF1 may be at an increased 
risk to develop chronic pain syndromes like 
CRPS since neurofibromin (the protein 
product of NF1) plays a key role in the 
excitability regulation of nociceptive sensory 
neurons 28. Avoidance or elimination of 
chronic inciting “pain generators” in CRPS is 
critical. Specifically in the case of glomus 
tumors, this is difficult to achieve in practice 
since the tumors are under-recognized and 
patients may have symptoms for years or 
decades before proper diagnosis 29,30. 
The recurrence rate following surgery ranged 
from 0% to 33.3% (30) While early 
recurrence may occur within weeks to months 
of surgery and presumably reflects inadequate 
excision, later recurrence (years) is extremely 
rare and it is probably the result of the 
development of a new tumor 31. 
Up to date several single report or case series 
studies on GT have been published 
21,24,25,27,32-42 (Table 1).  
The first association between GT and NF1 
was described on a leg of a young girl by 
Klaber in 1938 8. GT have been restricted in 
the subungual 32-34, to the fingers 21, 
fingers and toes 35 or described in multiple 
and different locations 24,35. Other 
researchers described GT in the thumb of a 
child 36, association between GT and a rare 
subtype of segmental neurofibromatosis 37 
or CPRS secondary to multiple GT of 
fingertips 38. Other studies have been 
recently published (between 2012-2014) 
27,25,38,39,40-42 where some authors have 
also clarified the genetic mechanisms that 
underlies the association between GT and the 
subtypes of NF1 27,25.  
The novelty of our report is the atypical 
localisation in the thenar eminence, compared 
to other cases described in the literature, that 
usually affects fingers and toes. 
The excision of GT in our patient results in 
complete pain relief and resolution of clinical 
symptoms. No recurrence was observed after 
2 years from surgery. 
No recurrence was observed in 2 years from 
surgery. We consider that the adoption of 
microsurgical glasses for inspecting the area 
after excision, may be helpful to avoid 
incomplete tumor removal. 
GT can be found in about 5% of patients with 
NF132. In most NF1 clinical programs, a 
routine screening for GT is not common and 
individuals with NF1 may experience pain 
from for up to 20 years before diagnosis 33. 
The relative rarity of these tumors, their small 
size, and their variable presentation often 
results in misdiagnosis and delayed treatment.  
The surgical approach reported in this study 
allow a faster solution, through an early 
clinical diagnosis, that can avoid the 
persistent and debilitating pain; furthermore, 
an early surgical approach can prevent an 
extensive demolition due to the neoplasm 
growth, with a minimum patient discomfort, 
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satisfactory cosmetic results and an improved 
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Legend of Figures  
Figure 1: Eminence thenar of the right hand 
with the areas where the neoformation was 
found (black arrows) and the Love test  was 
positive. 
Figure 2: Typical neurofibromas along the 
trunk and back of the patient  
Figure 3: Thermography show the 
hyperthermic area in the thenar eminence of 
the right hand where the glomus tumor was 
located (red arrow).  
Figure 4: Intraoperative findings. The glomus 
tumor was excised through a volar approach 
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and    was found to to be very shallow. The 
window on the left top shows the well 
capsulated neoformation as it appeared at the 
end of the procedure.   
Figure 5: Histological findings: blood vessels 
surrounded by a proliferation of small round 
cells with dark nuclei in a myxoid stroma.  
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